📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT. (2016)

First Author: Burns DM

Attributed to: A multi-disciplinary approach to understanding the immunological basis and potential prevention of graft versus host disease. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/bmt.2016.19

PubMed Identifier: 26901708

Publication URI: http://europepmc.org/abstract/MED/26901708

Type: Journal Article/Review

Volume: 51

Parent Publication: Bone marrow transplantation

Issue: 6

ISSN: 0268-3369